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Abstract
Background: The effects of preservatives of antiglaucoma medications on corneal surface and tear function have
been widely shown in literature; it’s not the same as regards the active compounds themselves. The purpose of our
study was to compare Ocular Surface Disease (OSD) signs and symptoms of Tafluprost 0.0015% versus preservative
free (PF) Timolol 0.1% eyedrops in ocular hypertensive (OH) and in primary open-angle glaucoma (POAG) patients.
Methods: A cross-sectional study included patients in monotherapy for at least 36 months with Tafluprost 0.0015%
(27) or PF Timolol 0.1% (24) and 20 healthy age and sex-matched volunteers. All subjects underwent clinical tests
(Schirmer I and break-up time), in vivo confocal microscopy (IVCM) and were surveyed using Ocular Surface Disease
Index (OSDI) and Glaucoma Symptoms Scale (GSS) questionnaires. The groups were compared with ANOVA,
Kruskal-Wallis test, t-test, Mann-Whitney test and Bonferroni’s adjustment of p-values.
Results: No significant differences were found in questionnaires scores, clinical tests, IVCM variables between
therapy groups. Tafluprost 0.0015% group showed significantly higher OSDI score, basal epithelial cells density,
stromal reflectivity, sub-basal nerves tortuosity (p = 0.0000, 0.037, 0.006, 0.0000) and less GSS score, number of
sub-basal nerves (p = 0.0000, 0.037) than controls but similar clinical tests results (p > 0.05). PF Timolol group
had significantly higher OSDI score, basal epithelial cells density, stromal reflectivity and sub-basal nerve tortuosity (p = 0.
000, 0.014, 0.008, 0.002), less GSS score, BUT and number of sub-basal nerves (p = 0.0000, 0.026, 0.003) than controls.
Conclusions: Compared to PF Timolol 0.1%, Tafluprost 0.0015% showed similar safety with regards to tear function and
corneal status and a similar tolerability profile. Both therapy groups show some alterations in corneal microstructure but
no side effects on tear function except for an increased tear instability in PF Timolol 0.1% group. Ophtalmologists should
be aware that even PF formulations may lead to a mild ocular surface impairment.
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Background
Glaucoma is an optic neuropathy with a multifactorial eti-
ology; the increased intraocular pressure (IOP) is the only
risk factor on which we can act and is thought to play the
main role in pathogenesis [1]. Medical treatment is usually
the first therapeutic choice to treat POAG and at present
prostaglandin analogs (PGA) and beta-blockers are the
initial therapies of choice worldwide [2].
There is growing evidence that the long term use of
antiglaucoma drugs may induce ocular surface toxicity
[3, 4], causing ocular surface disease and ocular discom-
fort [5, 6] which may affect patient’s quality of life and
compliance.
Previous studies have already pointed out that toxic
and proinflammatory effects of antiglaucoma ophtalmic
solutions are mainly due to preservatives [3, 4]; so to re-
duce discomfort and long term side effects and to in-
crease compliance to the topical therapy, preservative
free formulations have been developed as they have
shown to have an equivalent efficacy to the preserved
ones [7, 8].
PGA are a first line therapy option in treating elevated
intraocular pressure because of their good efficacy and
positive safety profile [9]. Tafluprost 0.0015% is the first
preservative free formulation of a PGF2a analog prepar-
ation; it was demonstrated to be well tolerated in naive
patients [10] and several studies showed an improve-
ment in tear osmolarity, BUT, tear fluid amount and tol-
erability in patients who switched from preserved drops
to PF Tafluprost and a good tolerability profile [11, 12].
Beta-blockers don’t induce any major local side ef-
fect except for a reduction in tear production linked
to beta-adrenergic receptor blockade in the lacrimal
glands [13]. However an increased expression of im-
munoinflammatory markers was observed in the con-
junctival epithelium of glaucoma patients treated with
non preserved timolol [14] and many side effects have
been shown for preserved beta-blockers, such as a re-
duction in corneal sensitivity, dry eye, punctate kera-
titis, conjunctival hyperemia [3, 15, 16], loss of goblet
cells in the conjunctiva [17].
Side effects of preservatives on corneal surface and
tear function have been widely shown in literature, it’s
not the same as regards active compounds themselves.
To our knowledge this is the first work which analyzes
in vivo and compares the effects of PF formulations of
Timolol and Tafluprost 0.0015%.
Methods
The purpose of this study was to evaluate and compare
the long term Ocular Surface Disease (OSD) signs, in
order to evaluate the safety, and symptoms, so to assess
tolerability, of Tafluprost 0.0015% and of preservative-
free timolol maleate 0.1% in OH and POAG patients by
means of clinical tests (Schirmer test I, BUT), in vivo
confocal microscopy and Ocular Surface Disease Index
(OSDI) and Glaucoma Symptoms Scale (GSS) question-
naires. Systemic side effects were also recorded so to
assess general safety.
In our study the safety of the medications concerns
the presence and amount of corneal and tear function
side effects as well as any systemic adverse event. The
tolerability of the drops, which represents the degree to
which overt adverse effects can be tolerated by the sub-
ject, is strictly linked with the adherence to the therapy
and was evaluated by the two questionnaires.
The study was carried out in accordance to the tenets
of the Declaration of Helsinki and it was approved by
the Local Ethical Committee. Informed consent was ob-
tained from all the subjects after the explanation of the
nature and possible consequences of the study.
In this single-masked, observational, cross-sectional
study three groups of subjects in care at the Glaucoma
service, Eye Clinic, University of Torino, were enrolled:
! Group 1: 54 eyes of 27 patients on topical PF
Tafluprost 0.0015% monotherapy for at least
36 months;
! Group 2: 48 eyes of 24 patients on topical
preservative free Timolol maleate 0.1% monotherapy
qd for at least 36 months;
! Control Group: 40 eyes of 20 healthy volunteers, age
and sex matched who met the following eligibility
criteria: negative history for inflammatory eye disease,
previous eye surgery (except for uncomplicated
cataract surgery within the last 6 months), ocular
trauma, allergic mucosal pathology. These subjects
didn’t use topical eyedrops (including artificial eye
drops) or contact lens and didn’t suffer from current
or previous local or systemic disease that could
involve the cornea.
The inclusion criteria for Group 1 and 2 were the fol-
lowing: age 18 years or older, diagnosis of POAG or OH
on preservative free PGA or timolol eye drops mono-
therapy for at least 36 months.
The exclusion criteria for Group 1 and 2 were the fol-
lowing: previous history of intraocular surgery (except for
uncomplicated cataract surgery within the last 6 months)
or argon laser trabeculoplasty, contact lenses use, recent
ocular inflammation, previous or current use of other eye-
drops including artificial tear therapy, systemic therapy
known to alter tear production, autoimmune diseases,
previous severe ocular trauma, any history or biomicro-
scopy evidence of eye surface impairment.
All subjects were queried for ocular symptoms by
OSDI and GSS questionnaires then they underwent a
complete ophthalmic examination, BUT, Schirmer I test,
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in vivo corneal confocal examination (IVCM) and
Goldmann applanation tonometry performed 30 min
after previous tests. IVCM was performed with a cor-
neal confocal scanning-laser microscope (HRT II Ros-
tock Cornea Module; Heidelberg Engineering GmbH,
Heidelberg, Germany), that uses a 670 nm red wave-
lenght Helium Neon diode laser source. It is a Class I
laser so it doesn’t carry risks of ocular injury.The
confocal laser scanning device uses a ×60 objective
water immersion lens and a working distance of 0 to
3 mm from the applanating cap. The two-dimensional
images acquired are defined by 384 × 384 pixels over
an area of 400 μm, with lateral digital resolution of
1 μm/pixel and a depth resolution of 2 μm/pixel. The
optical section thickness is 4 μm.
The eye being examined was anesthetized with benoxi-
nate hydrochloride 0.4% (oxybuprocaine hydrochloride,
ALFA INTES; Industria Terapeutica Splendore S.r.l,
Casoria, Italy) eye drops. A drop of Viscotirs gel (0.2%
polyacrylic gel, Medivis, Catania, Italy) was used as a
coupling material between the polymethilmethacylate
contact cap of the objective and the corneal apex. The
examiner aligned the objective lens on the corneal apex
while the patient was looking at the flashing light. The
objective lens was moved towards slowly until it came in
contact with the corneal apex. Several sweeps of the en-
tire depth of the cornea were achieved. The examination
took 3 to 5 min and was performed on all the subjects
enrolled by the same examiner.
Images were analyzed by the same masked investigator
using the same light condition. The best images for each
patient were chosen and the mean value of 3 images for
each parameter studied was considered for statistical
analysis. We analyzed the following parameters:
! Basal Epithelial cell density (cell/mm2): the manual
cell counting procedure of the software was used to
perform the cell count in the 400 μm area analyzed;
cells only partially contained in this area were not
considered in the count.
! Stromal reflectivity (keratocytes activation): just the
anterior stromal layer was considered for the
analysis and its reflectivity was evaluated by means
of a grading scale from 0 to 4 [3], considering the
reflectivity of cellular elements with respect to
background.
! Number of sub-basal nerves: sum of the nerve
branches longer than 50 μm present in a frame of
the sub-basal nerve plexus.
! Sub-basal nerve tortuosity: defined by the frequency
and the amplitude of the variations in the nerve
fiber orientation. It was assessed by a pre-existing
scale (0: straight nerve fibers; 4: highly convoluted
nerve fibers) [3]
! Sub-basal nerve reflectivity: classified in 4 grades
according to a pre-existing scale (1: low reflectivity;
4: very bright reflectivity) [3].
! Endothelial cell density: assessed by the manual cell
counting system of the software in the 400 μm area
examined.
Statistical analysis
Normal distribution of the variables was evaluated
using the Shapiro-Wilk W test. On the basis of data
distribution, the groups were compared with ANOVA
or Kruskal-Wallis test for continuous variables; t-test
or Mann-Whitney test and Bonferroni’s adjustment of
p-values were used for post-hoc comparisons.
Demographic and clinical features of subjects were an-
alyzed by descriptive statistics. OSDI and GSS scores,
Schirmer I test results, BUT, basal epithelial cell density,
stromal reflectivity, number of sub-basal nerves, sub-
basal nerve tortuosity and reflectivity and endothelial
cell density were considered for statistical analysis.
P values <0.05 were considered statistically significant.
Statistical analysis was performed using the software
STATA® SE 12.1.
Results
Seventyone Caucasian subjects were enrolled. Demo-
graphic features of the subjects are shown in Table 1.
Mean age and gender were not significantly different
between the three groups.
Clinical data (Schirmer I test and BUT), questionnaires
scores and confocal microscopy data comparisons be-
tween therapy groups, between Tafluprost and control
groups and between PF Timolol and control groups are
reported in Table 2.
Clinical data, OSDI and GSS scores, confocal micros-
copy parameters (basal epithelial cell density, number of
sub-basal nerves, stromal reflectivity, sub-basal nerve
tortuosity, sub-basal nerve reflectivity, endothelial dens-
ity) were not significantly different between the two
therapy groups (p > 0.05). Conversely the number of
sub-basal nerves was significantly higher in controls
rather than in Tafluprost or PF Timolol groups (p < 0.05
and p < 0.01 respectively). Epithelial cell density, stromal
reflectivity, sub-basal nerves tortuosity were significantly
lower in controls than in Tafluprost (p < 0.05, p < 0.01
and p < 0.0001 respectively) and in PF Timolol
(p < 0.05,p < 0.01and p < 0.01 respectively) groups.
As regards clinical data, sub-basal nerve reflectivity
and endothelial density no difference was found be-
tween Tafluprost and control groups (p > 0.05). Schir-
mer I test value, sub-basal nerve reflectivity and
endothelial density were not significantly different be-
tween PF Timolol and control groups (p > 0.05). On
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the contrary BUT was significantly higher in controls
than in PF Timolol group (p < 0.05).
Highly significant differences were observed as regards
questionnaires scores between Tafluprost and PF Timolol
groups and controls (p < 0.0001). No patient had any sys-
temic side effects. Table 3 shows OSDI scores distribution.
Figure 1 shows the increased stromal reflectivity, the
lower number of sub-basal nerves and their higher tor-
tuosity in Tafluprost and PF Timolol groups with respect
to controls. Figure 2 shows the values of IVCM parame-
ters in the three groups.
Discussion
To the best of our knowledge no previous studies com-
pared Tafluprost and PF Timolol in terms of tear func-
tion and corneal layers morphology; just Chabi et al.
compared their tolerability and safety resulting in a simi-
lar incidence of drug related adverse events, discontinu-
ation attributable to them and tolerability [18].
Our data show that patients treated either with Taflu-
prost or PF Timolol don’t differ in clinical signs and
symptoms.
On the other hand the comparison with controls re-
veals significant differences in some corneal parameters
analyzed by IVCM suggesting a side effect of the active
compounds on the corneal layers after a long term
therapy.
The IVCM data of our control group are comparable
to those available in literature for IVCM of normal pa-
tients. We found significant differences between IVCM
parameters of Tafluprost and control groups which con-
firm previous findings on the proinflammatory effect of
PGA [19, 20]. In particular we observed an increase of
the activation of anterior stromal keratocytes in accord-
ance with Fogagnolo et al.’s findings [20]. PGA treat-
ments seem to increase inflammatory cytokines in the
ocular surface which in turn stimulate metalloprotein-
ases (MMPs) [19]; it was reported that metalloprotein-
ases increase the keratocytes density [21] and cause a
thinning of central corneal thickness [19] so we suppose
that the corneal alterations observed may be the result
of the upregulation of MMPs.
In contrast to our findings a recent paper didn’t ob-
serve significant changes in corneal parameters in naive
patients after 12 months of Tafluprost therapy [22]. The
difference in results may be due to the different IVCM
employed and treatment duration; little is known on the
time of occurrence of corneal changes after starting anti-
glaucomatous therapies; it may take the corneal alter-
ations more than 12 months to occur.
Corneal alterations were also found in PF Timolol
group, these could be due to the subclinical inflamma-
tion present in corneal tissues exposed for a long time to
beta-blockers. Baudouin et al. noted that PF Timolol in-
duces an overexpression of inflammatory interleukins in
conjunctival epithelial cells [14]. Ishibashi et al. reported
that PF Timolol disrupts the corneal epithelial barrier
function even though to a lesser extent than preserved
Timolol [15]. We found less number of sub-basal nerves
and an higher sub-basal nerve tortuosity in PF Timolol
group than in controls in accordance with Martone et
al.’s findings [3]. We also found an higher stromal
activation in PF Timolol group than in controls, in con-
trast with Martone et al.’s data [3]. These discordant
findings may be due both to differences in the study
populations (higher duration of therapy in our study)
and to the poor interobserver reproducibility of IVCM.
Before drawing final conclusions from our confocal
data it must be underlined that subclinical corneal pat-
terns were found even in untreated OH and POAG pa-
tients, although to a less extent with respect to those
observed after 12 months of therapy [20]. Therefore our
findings could in part have already existed before the be-
ginning of therapies.
As regards clinical data patients in therapy with PF
Timolol showed a significant shorter BUT than controls
in accordance with Kuppens et al. [13] whereas Martone
et al. reported a reduction of both Schirmer I test and
BUT values in PF Timolol patients [3]. On the other
hand Tafluprost treated patients showed no alterations
of lacrimal function in accordance with the current
Table 1 Demographic features of subjects enrolled in the study
PF Tafluprost 0.0015% group PF Timolol 0.1% group Control group
Patients 27 24 20
Eyes 54 48 40
Age (years) 65.11 ± 10.16 65.08 ± 10.79 64.85 ± 9.76
Gender (male/female) 15/12 13/11 12/8
Diagnosis 54POAG 46POAG/2OH /
Treatment Duration (months) 42.93 ± 6.04 44.38 ± 8.22 -
IOP (mmHg) 16.61 ± 2.01 16.31 ± 2.86 14.50 ± 1.93
Age, treatment duration and IOP are expressed by mean ± standard deviation
PF preservative free, IOP intraocular pressure
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literature [10, 20, 23]; this might be due to a favourable
long term influence of Tafluprost on goblet cells [23].
In spite of the signs observed both therapies have a
similar overall good tolerability. OSD detected through
the questionnaires may be classified as absent or mild in
the majority of cases; none of Tafluprost group and just
6.67% of patients in PF Timolol therapy reported a se-
vere ocular surface disease when queried by OSDI
questionnaire.
This study has some limitations, which in part reflect
the limits of confocal microscopy. We examined just the
central cornea, IVCM is a subjective quali-quantitative
exam and the meanings of some findings are still un-
clear: what nerve fibers tortuosity or reflectivity stand
for is debated [3, 24]. Another limitation of this study is
that it was not prospective. Finally it’s uncertain if ocular
surface and corneal alterations observed in patients
treated with preservative free eyedrops are due to the ac-
tive compound itself or rather the eccipients. Therefore
further studies are required to investigate this issue.
Conclusions
We found some corneal alterations in both groups, so
the active compound itself may lead to an ocular surface
impairment. Tafluprost doesn’t affect tear stability in
contrast with PF Timolol; this fact could be of particular
benefit in patients with dry eye disease or with an
Table 3 OSDI scores distribution
PF Tafluprost 0.0015% group PF Timolol 0.1% group Total
0 (n°) 13 12 25
(%) 48.15 50 49.02
1 (n°) 12 7 19
(%) 44.44 29.17 37.25
2 (n°) 2 4 6
(%) 7.41 16.67 11.76
3 (n°) 0 1 1
(%) 0.00 4.17 1.96
Total (n°) 27 24 51
(%) 100.00 100.00 100.00
The overall OSDI score defines the ocular surface as: 0- normal (0-12points) or
having 1-mild (13–22 points), 2-moderate (23-32points), 3- severe (33–100
points) disease
Fig. 1 In vivo corneal confocal microscopy findings in Tafluprost 0.0015% group, controls and PF Timolol 0.1% group. a Tafluprost 0.0015% group;
b Control group; c PF Timolol 0.1% group. The basal epithelium layer images show a significant increase of cell density in therapy groups with respect
to control group; no difference appears between Tafluprost and PF Timolol groups. The sub-basal nerve plexus figures show a reduction of the number
of nerve fibers with higher tortuosity scores in patients on therapy with respect to controls; Tafluprost and PF timolol groups don’t differ in sub-basal
nerve number and morphology. Stromal images underline a significantly higher keratocytes hyperreflective network in therapy groups than in controls.
Stromal reflectivity is similar in Tafluprost and PF Timolol groups. The endothelial images show a similar mosaic pattern in the three groups
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already disrupted ocular surface. Finally we showed that
both IOP lowering drops lead to a low to mild severity
of ocular discomfort, without significant differences be-
tween them.
In conclusion both PF Tafluprost and PF Timolol have
a comparable 36 months safety and tolerability. On the
basis of our results clinicians should be aware that even
PF formulations may induce OSD even though to a less
extent than preserved ones. As recommended by EGS
guidelines [25] a careful evaluation of individual target
therapy with the least amount of medication to achieve
the therapeutic response should be a consistent goal.
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